Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shailendra Verma

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Expert Review of Anticancer Therapy|July 13, 2002
Dose-intensive chemotherapy in advanced adult soft tissue sarcomaShailendra Verma, Vivien Bramwell
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 29, 2003
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancerShailendra Verma, Angela Rocchi
The Oncologist|May 30, 2003
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancerShailendra Verma, A Lane Ilersich
American Journal of Clinical Oncology|June 11, 2003
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifenGeorge Dranitsaris, Shailendra Verma, Maureen Trudeau
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 9, 2008
The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyondAngela Rocchi, Devidas Menon, Shailendra Verma, et al.
Case Reports in Oncology|June 20, 2017
Systemic Therapy Outcomes in Adult Patients with Ewing Sarcoma Family of TumorsMario Valdes, Garth Nicholas, Shailendra Verma, et al.
Patient Education and Counseling|October 21, 2016
An exploratory study of patients' views about being at high-risk for breast cancer and risk management beliefs and intentions, before and after risk counselling: Preliminary evidence of the influence of beliefs on post-counselling prevention intentionsLise Paquet, Lisa Simmonds, Charles Yang, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|February 27, 2003
Development and evaluation of a breast cancer prevention decision aid for higher-risk womenDawn Stacey, Annette M O'Connor, Cathy DeGrasse, et al.
Cancer|June 27, 2007
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancerNancy A Risebrough, Shailendra Verma, Maureen Trudeau, et al.
Breast Cancer Research and Treatment|October 9, 2014
Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature reviewPeter Andrew, Sabira Valiani, Jennifer MacIsaac, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Expert Review of Anticancer Therapy|July 13, 2002
Dose-intensive chemotherapy in advanced adult soft tissue sarcomaShailendra Verma, Vivien Bramwell
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 29, 2003
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancerShailendra Verma, Angela Rocchi
The Oncologist|May 30, 2003
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancerShailendra Verma, A Lane Ilersich
American Journal of Clinical Oncology|June 11, 2003
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifenGeorge Dranitsaris, Shailendra Verma, Maureen Trudeau
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 9, 2008
The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyondAngela Rocchi, Devidas Menon, Shailendra Verma, et al.
Case Reports in Oncology|June 20, 2017
Systemic Therapy Outcomes in Adult Patients with Ewing Sarcoma Family of TumorsMario Valdes, Garth Nicholas, Shailendra Verma, et al.
Patient Education and Counseling|October 21, 2016
An exploratory study of patients' views about being at high-risk for breast cancer and risk management beliefs and intentions, before and after risk counselling: Preliminary evidence of the influence of beliefs on post-counselling prevention intentionsLise Paquet, Lisa Simmonds, Charles Yang, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|February 27, 2003
Development and evaluation of a breast cancer prevention decision aid for higher-risk womenDawn Stacey, Annette M O'Connor, Cathy DeGrasse, et al.
Cancer|June 27, 2007
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancerNancy A Risebrough, Shailendra Verma, Maureen Trudeau, et al.
Breast Cancer Research and Treatment|October 9, 2014
Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature reviewPeter Andrew, Sabira Valiani, Jennifer MacIsaac, et al.
Pageof 6